Special Issue

New Biomolecules and Drug Delivery Systems as Alternatives to Conventional Antibiotics

Message from the Guest Editor

New approaches to deal with the growing concern associated with antibiotic-resistant bacteria are in great demand. For many years, antibiotics have been widely employed to treat infections. However, their excessive consumption and misuse have accelerated the rise of antibiotic-resistant microorganisms, which constitute one of the dominant challenges to global health. The antibiotic crisis is now a general concern and alternative biomolecules or drug delivery systems to treat infections are, therefore, urgently needed. From natural extracts to traditional medicine remedies, to newly engineered nanocapsules and nanoparticles to bio-based, biodegradable delivery platforms, many systems to fight infections have been proposed. This Special Issue seeks manuscript submissions that further our understanding of the antimicrobial action of specialized biomolecules, recently engineered or chemically modified from their ancient origins, as alternatives to conventional antibiotics.

Guest Editor

Dr. Helena Felgueiras

Centre for Textile Science and Technology, University of Minho, Campus de Azurém, 4800-058 Guimarães, Portugal

Deadline for manuscript submissions

closed (31 December 2021)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/60758

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI